Cargando…

Clinical Use of Aspirin in Treatment and Prevention of Cardiovascular Disease

Cardiovascular disease (CVD), principally heart disease and stroke, is the leading cause of death for both males and females in developed countries. Aspirin is the most widely used and tested antiplatelet drug in CVD, and it is proven to be the cornerstone of antiplatelet therapy in treatment and pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Yuxiang, Ge, Junbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236445/
https://www.ncbi.nlm.nih.gov/pubmed/22195280
http://dx.doi.org/10.1155/2012/245037
_version_ 1782218745440108544
author Dai, Yuxiang
Ge, Junbo
author_facet Dai, Yuxiang
Ge, Junbo
author_sort Dai, Yuxiang
collection PubMed
description Cardiovascular disease (CVD), principally heart disease and stroke, is the leading cause of death for both males and females in developed countries. Aspirin is the most widely used and tested antiplatelet drug in CVD, and it is proven to be the cornerstone of antiplatelet therapy in treatment and prevention of CVD in clinical trials in various populations. In acute coronary syndrome, thrombotic stroke, and Kawasaki's disease, acute use of aspirin can decrease mortality and recurrence of cardiovascular events. As secondary prevention, aspirin is believed to be effective in acute coronary syndrome, stable angina, revascularization, stroke, TIA, and atrial fibrillation. Aspirin may also be used for patients with a high risk of future CVD for primary prevention, but the balance between benefits and the possibility of side effects must be considered.
format Online
Article
Text
id pubmed-3236445
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-32364452011-12-22 Clinical Use of Aspirin in Treatment and Prevention of Cardiovascular Disease Dai, Yuxiang Ge, Junbo Thrombosis Review Article Cardiovascular disease (CVD), principally heart disease and stroke, is the leading cause of death for both males and females in developed countries. Aspirin is the most widely used and tested antiplatelet drug in CVD, and it is proven to be the cornerstone of antiplatelet therapy in treatment and prevention of CVD in clinical trials in various populations. In acute coronary syndrome, thrombotic stroke, and Kawasaki's disease, acute use of aspirin can decrease mortality and recurrence of cardiovascular events. As secondary prevention, aspirin is believed to be effective in acute coronary syndrome, stable angina, revascularization, stroke, TIA, and atrial fibrillation. Aspirin may also be used for patients with a high risk of future CVD for primary prevention, but the balance between benefits and the possibility of side effects must be considered. Hindawi Publishing Corporation 2012 2011-11-24 /pmc/articles/PMC3236445/ /pubmed/22195280 http://dx.doi.org/10.1155/2012/245037 Text en Copyright © 2012 Y. Dai and J. Ge. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Dai, Yuxiang
Ge, Junbo
Clinical Use of Aspirin in Treatment and Prevention of Cardiovascular Disease
title Clinical Use of Aspirin in Treatment and Prevention of Cardiovascular Disease
title_full Clinical Use of Aspirin in Treatment and Prevention of Cardiovascular Disease
title_fullStr Clinical Use of Aspirin in Treatment and Prevention of Cardiovascular Disease
title_full_unstemmed Clinical Use of Aspirin in Treatment and Prevention of Cardiovascular Disease
title_short Clinical Use of Aspirin in Treatment and Prevention of Cardiovascular Disease
title_sort clinical use of aspirin in treatment and prevention of cardiovascular disease
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236445/
https://www.ncbi.nlm.nih.gov/pubmed/22195280
http://dx.doi.org/10.1155/2012/245037
work_keys_str_mv AT daiyuxiang clinicaluseofaspirinintreatmentandpreventionofcardiovasculardisease
AT gejunbo clinicaluseofaspirinintreatmentandpreventionofcardiovasculardisease